Should I buy or sell Theravance Biopharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TBPH shares. View TBPH analyst ratings or view top-rated stocks .

What is Theravance Biopharma's stock price target for 2024?

2 brokerages have issued 12-month target prices for Theravance Biopharma's stock. Their TBPH share price targets range from $20.00 to $21.00. On average, they anticipate the company's stock price to reach $20.50 in the next year. This suggests a possible upside of 119.5% from the stock's current price. View analysts price targets for TBPH or view top-rated stocks among Wall Street analysts .

How have TBPH shares performed in 2024?

Theravance Biopharma's stock was trading at $11.24 at the start of the year. Since then, TBPH stock has decreased by 16.9% and is now trading at $9.34. View the best growth stocks for 2024 here .

When is Theravance Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our TBPH earnings forecast .

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) issued its quarterly earnings data on Monday, February, 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.02. The biopharmaceutical company had revenue of $17.57 million for the quarter, compared to the consensus estimate of $17.49 million. Theravance Biopharma had a negative net margin of 96.12% and a negative trailing twelve-month return on equity of 19.31%.

What ETFs hold Theravance Biopharma's stock?

ETFs with the largest weight of Theravance Biopharma (NASDAQ:TBPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP) , SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . iShares U.S. Pharmaceuticals ETF (IHE) .

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD) , Bausch Health Companies (BHC) , Exelixis (EXEL) , SCYNEXIS (SCYX) , Teva Pharmaceutical Industries (TEVA) , Johnson & Johnson (JNJ) , Merck & Co., Inc. (MRK) , Idera Pharmaceuticals (IDRA) , Pfizer (PFE) and TG Therapeutics (TGTX) .

How do I buy shares of Theravance Biopharma?

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TBPH

Theravance Biopharma (TBPH) Stock Price, News & Analysis

→ The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad)

Free TBPH Stock Alerts

$9.34

+0.14 (+1.52%)

(As of 04/19/2024 ET)

Compare

Today's Range: $9.02
▼
$9.38
50-Day Range: $8.35
▼
$9.92
52-Week Range: $8.21
▼
$11.98

Volume: 433,019 shs
Average Volume: 399,447 shs
Market Capitalization: $453.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.50

Get Theravance Biopharma alerts:

Theravance Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 119.5% Upside
$20.50 Price Target
Short Interest: Bearish
17.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 13 Articles This Week
Insider Trading: Selling Shares
$10,922 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.84) to ($0.33) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.07 out of 5 stars

Medical Sector

556th out of 911 stocks

Pharmaceutical Preparations Industry

252nd out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Theravance Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Theravance Biopharma has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
17.16% of the float of Theravance Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Theravance Biopharma has a short interest ratio ("days to cover") of 20.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Theravance Biopharma has recently decreased by 10.48%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Theravance Biopharma does not currently pay a dividend.
Dividend Growth
Theravance Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TBPH.

2.0

News and Social Media Coverage

News Sentiment
Theravance Biopharma has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Theravance Biopharma this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Theravance Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,922.00 in company stock.
Percentage Held by Insiders
Only 6.90% of the stock of Theravance Biopharma is held by insiders.
Percentage Held by Institutions
99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Theravance Biopharma are expected to grow in the coming year, from ($0.84) to ($0.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Theravance Biopharma is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Theravance Biopharma is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Theravance Biopharma has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

About Theravance Biopharma Stock (NASDAQ:TBPH)

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

TBPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TBPH Stock News Headlines

April 18, 2024 | americanbankingnews.com

Theravance Biopharma, Inc. Expected to Earn FY2024 Earnings of ($0.89) Per Share (NASDAQ:TBPH)

April 17, 2024 | msn.com

Theravance Biopharma (TBPH) Price Target Increased by 10.00% to 15.71

April 20, 2024 | DTI (Ad)

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

April 17, 2024 | americanbankingnews.com

Q1 2026 Earnings Estimate for Theravance Biopharma, Inc. (NASDAQ:TBPH) Issued By Zacks Research

April 15, 2024 | investorplace.com

BTIG Research Predicts Over 118% Rally for These 3 Stocks

April 14, 2024 | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from Analysts at BTIG Research

April 10, 2024 | finance.yahoo.com

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

April 10, 2024 | prnewswire.com

April 20, 2024 | DTI (Ad)

Start loving Mondays like this

March 12, 2024 | investorplace.com

Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics

March 7, 2024 | markets.businessinsider.com

Analyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment Potential

February 28, 2024 | markets.businessinsider.com

Theravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestones

February 28, 2024 | finance.yahoo.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript

February 27, 2024 | stockhouse.com

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 27, 2024 | investing.com

Theravance Biopharma Inc (TBPH)

February 27, 2024 | markets.businessinsider.com

Balancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharma

February 26, 2024 | msn.com

Theravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03M

February 26, 2024 | prnewswire.com

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 25, 2024 | seekingalpha.com

Theravance Biopharma Q4 2023 Earnings Preview

February 24, 2024 | benzinga.com

Theravance Biopharma Stock (NASDAQ:TBPH) Dividends: History, Yield and Dates

February 24, 2024 | msn.com

Theravance Biopharma (TBPH) Price Target Increased by 5.77% to 14.03

February 22, 2024 | prnewswire.com

Theravance Biopharma to Participate in an Upcoming Investor Conference

February 15, 2024 | finance.yahoo.com

Will Theravance Biopharma (NASDAQ:TBPH) Spend Its Cash Wisely?

February 14, 2024 | finance.yahoo.com

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

February 14, 2024 | prnewswire.com

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

February 1, 2024 | finance.yahoo.com

Theravance Biopharma, Inc. (TBPH)

January 19, 2024 | finance.yahoo.com

Analysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Long

See More Headlines

Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TBPH
Previous Symbol: NASDAQ:TBPHV
CUSIP: N/A
CIK: 1583107
Web: www.theravance.com
Phone: (650) 808-6000
Fax: N/A
Employees: 359
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.50
High Stock Price Target: $21.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +119.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,190,000.00
Net Margins: -96.12%
Pretax Margin: -85.80%
Return on Equity: -19.31%
Return on Assets: -12.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.39
Quick Ratio: 5.39

Sales & Book Value

Annual Sales: $57.42 million
Price / Sales: 7.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.28 per share
Price / Book: 2.18

Miscellaneous

Outstanding Shares: 48,560,000
Free Float: 45,209,000
Market Cap: $453.55 million
Optionable: Optionable
Beta: 0.36

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Rick E. Winningham
Chairman & Chief Executive Officer
Andrew Asa Hindman
Chief Financial Officer & Senior Vice President
Vijay Sabesan
Senior Vice President-Technical Operations
Philip D. Worboys
Senior VP-Research & Translational Science
Bradford J. Shafer
Secretary, Executive VP & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TBPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Theravance Biopharma stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TBPH shares.
View TBPH analyst ratings or view top-rated stocks.
What is Theravance Biopharma's stock price target for 2024?: 2 brokerages have issued 12-month target prices for Theravance Biopharma's stock. Their TBPH share price targets range from $20.00 to $21.00. On average, they anticipate the company's stock price to reach $20.50 in the next year. This suggests a possible upside of 119.5% from the stock's current price.
View analysts price targets for TBPH or view top-rated stocks among Wall Street analysts.
How have TBPH shares performed in 2024?: Theravance Biopharma's stock was trading at $11.24 at the start of the year. Since then, TBPH stock has decreased by 16.9% and is now trading at $9.34.
View the best growth stocks for 2024 here.
When is Theravance Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our TBPH earnings forecast.

How were Theravance Biopharma's earnings last quarter?: Theravance Biopharma, Inc. (NASDAQ:TBPH) issued its quarterly earnings data on Monday, February, 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.02. The biopharmaceutical company had revenue of $17.57 million for the quarter, compared to the consensus estimate of $17.49 million. Theravance Biopharma had a negative net margin of 96.12% and a negative trailing twelve-month return on equity of 19.31%.
What ETFs hold Theravance Biopharma's stock?: ETFs with the largest weight of Theravance Biopharma (NASDAQ:TBPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).
What other stocks do shareholders of Theravance Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).
How do I buy shares of Theravance Biopharma?: Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TBPH) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial